<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/64BC5E73-972F-41E1-A12C-D97DC9BDFB93"><gtr:id>64BC5E73-972F-41E1-A12C-D97DC9BDFB93</gtr:id><gtr:name>MRC Clinical Sciences Centre</gtr:name><gtr:address><gtr:line1>Faculty of Medicine Imperial College</gtr:line1><gtr:line2>London Hammersmith Campus</gtr:line2><gtr:line3>Du Cane Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W12 0NN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/64BC5E73-972F-41E1-A12C-D97DC9BDFB93"><gtr:id>64BC5E73-972F-41E1-A12C-D97DC9BDFB93</gtr:id><gtr:name>MRC Clinical Sciences Centre</gtr:name><gtr:address><gtr:line1>Faculty of Medicine Imperial College</gtr:line1><gtr:line2>London Hammersmith Campus</gtr:line2><gtr:line3>Du Cane Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W12 0NN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0B7BA49E-A505-41DC-AB71-A59E5DEB972E"><gtr:id>0B7BA49E-A505-41DC-AB71-A59E5DEB972E</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Grasby</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U120031869"><gtr:id>0AD81866-3BE8-4EB5-AB9A-B24113A1EA38</gtr:id><gtr:title>PET Psychiatry</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U120031869</gtr:grantReference><gtr:abstractText>Major Depression and Schizophrenia account for a substantial proportion of the health care budget, with Major Depression predicted to become the second most important cause of medical morbidity by the year 2020. Understanding the neurochemical and functional changes occurring in patients with depressive disorders, schizophrenia, or those at risk of developing these illnesses, will not only advance our understanding of pathophysiology but will be necessary for radically improving current drug treatments, most of which are sub-optimal. The Neuroimaging of Psychiatric Illness with PET and MRI programme aims to discover neurochemical changes that underlie the complex, multifactorial illnesses of Major Depression, Schizophrenia, or their sub-syndromes and to further understand the pharmacological mechanisms of psychotropic drug treatments. The neurochemical focus remains, in large part, on 5-HT and Dopamine neurotransmission. Clinical studies, as well as involving established patient populations, focus on individuals deemed to be at risk of major depression and schizophrenia in an attempt to discover trait neurochemical abnormalities for these conditions. In addition, the programme aims to develop and validate pharmacologic fMRI paradigms for indexing neurotransmitter systems of relevance to depression and schizophrenia and to test novel radiotracers for psychiatry research.</gtr:abstractText><gtr:technicalSummary>Neuroimaging of Psychiatric Illness with PET and MRI. The groups work is focussed on discovering neurochemical and functional changes that underlie the complex, multi-factorial illnesses of Major Depression, Schizophrenia, or their sub-syndromes and to further understand the pharmacological mechanisms of conventional and novel psychotropic drug treatments. The neurochemical focus remains, in large part, on 5-HT and DA neurotransmission, although basic investigations of GABAergic and Glutamatergic systems are planned. Studies are a combination of preclinical and clinical experiments using both PET and recently acquired fMRI. Basic studies are orientated toward novel methods for indexing DA and 5-HT neurotransmission and psychotropic drug action in the human brain. Clinical studies, as well as involving established patient populations, particularly focus on individuals deemed to be at risk of major depression and schizophrenia in an attempt to discover trait neurochemical abnormalities for these conditions.||Specific Objectives||1) Develop/optimise PET scanning protocols for the detection of endogenousDA and 5-HT neurotransmitter release- application to major Depression and Schizophrenia.||2) Undertake a comprehensive assessment of 5-HTT, 5-HT2A, and 5-HT1A receptors as state or trait markers in depressive illness.||3) Examine dopaminergic function in prodromal patients at risk of schizophrenia.||4) Develop and validate pharmacologic fMRI paradigms for indexing neurotransmitter systems of relevance to depression and schizophrenia.||5) Utilise conjoint fMRI and PET neurochemical measures to examine the effects of genetic polymorphisms on brain function and neurochemistry relevant to major psychiatric illness.||6) Test novel radiotracers for psychiatry research.</gtr:technicalSummary><gtr:fund><gtr:end>2008-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1993-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>6421741</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_U120031869</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>